Another delay for a long awaited drug

July 1, 2014

The introduction of Levadex has been delayed again, this time for a year. It seems like deja vu all over again – I wrote the same thing on this blog in April of last year. Levadex, which the manufacturer (Allergan) just renamed as Semprana, is an inhaler containing DHE. DHE, or dihydroergotamine is one of the most effective injectable drugs for migraine. It should be even better in an inhaled form because it works faster and causes much less nausea than the injection. The FDA is again delaying the launch because of manufacturing problems. Apparently, the particle size of the drug when it comes out of the inhaler is not uniform enough. Many patients are unhappy, but I am sure that the Allergan is very unhappy too since they spent almost a billion dollars to acquire this drug from a small company that developed it.

Written by
Alexander Mauskop, MD
Continue reading
October 21, 2025
Alternative Therapies
Meditation is better than slow breathing exercise in reducing pain
A new study published in the journal PAIN by Dr. A. Amorim and her colleagues at the University of California San Diego examined how mindfulness meditation reduces pain. The findings help clarify whether mindfulness meditation is more effective than simple slow breathing for pain relief.
Read article
September 7, 2025
How Artificial Sweeteners May Be Affecting Your Brain
A large Brazilian study published in Neurology followed nearly 13,000 adults for eight years and found something troubling: people who consumed the most artificial sweeteners showed faster cognitive...
Read article
August 30, 2025
Lithium Levels are low in Alzheimer’s. Is there a role in Migraine and Chronic Pain?
Recently published research on lithium deficiency in Alzheimer’s disease has caught the attention of the media. As a neurologist specializing in pain and headache medicine with an interest in no...
Read article